TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02601573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.
Study: NCT02491229

Intervention type: OTHER
Group type: OTHER
Intervention: LOGI diet
Description: For twelve weeks, this group eats meals according to the Low Glycemic and Insulinemic Diet (LOGI).
Study: NCT00540618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-507
Description: Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-507
Description: Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)
Study: NCT01762709

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The VT 8 ml/kg group
Description: the dependent lung will be ventilated with a TV of 8 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
Study: NCT04142970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSK3486
Description: HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSK3486
Description: HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
Study: NCT00540618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-507
Description: Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)
Study: NCT03826784

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BHA
Description: BHA active ingredients include a blood-derived component and beta-tricalcium phosphate. It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.
Study: NCT01155167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin and lidocaine
Description: Topical Nitroglycerin and lidocaine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04796064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-intensity aerobic training
Description: A low-intensity aerobic training group started with 15 minutes of warm-up, which includes static stretching of the upper and lower limb muscles. then participants were instructed to do 30 minutes of low-intensity aerobic training exercises, which include 20 minutes on the treadmill and 10 minutes of cycle ergometer, followed by 10 minutes of cool down.~- In high-intensity training (HAT) the same protocol has been followed, but the intensity of exercises was fixed between 60% to 80 % of maximum heart rate. The strength training includes major group muscles such as shoulder flexors, extensors, and abductors, elbow flexors and extensors, hip flexors\& extensors, knee flexors\&extensors, abdominal and back muscles also were trained. Each group of muscles was trained for 10 repetitions for 3 sets with a rest period of 5 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-intensity aerobic training
Description: A low-intensity aerobic training group started with 15 minutes of warm-up, which includes static stretching of the upper and lower limb muscles. then participants were instructed to do 30 minutes of low-intensity aerobic training exercises, which include 20 minutes on the treadmill and 10 minutes of cycle ergometer, followed by 10 minutes of cool down.~- In high-intensity training (HAT) the same protocol has been followed, but the intensity of exercises was fixed between 60% to 80 % of maximum heart rate. The strength training includes major group muscles such as shoulder flexors, extensors, and abductors, elbow flexors and extensors, hip flexors\& extensors, knee flexors\&extensors, abdominal and back muscles also were trained. Each group of muscles was trained for 10 repetitions for 3 sets with a rest period of 5 minutes.
Study: NCT02572739

Intervention type: DEVICE
Intervention: PICCO
Description: measurements based on thermodilution

Intervention type: DEVICE
Intervention: NICCOMO
Description: measurements based on impedance
Study: NCT03757390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exforge® tab 5/160mg, Crestor® tab 10mg
Description: co-administration of Amlodipine 5mg/Valsartan 160mg(combination drug) and Rosuvastation 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exforge® tab 5/160mg, Crestor® tab 10mg
Description: co-administration of Amlodipine 5mg/Valsartan 160mg(combination drug) and Rosuvastation 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30060 5/160/10mg
Description: Fixed-dose combination drug containing Amlodipine 5mg and Valsartan 160mg and Rosuvastatin 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30060 5/160/10mg
Description: Fixed-dose combination drug containing Amlodipine 5mg and Valsartan 160mg and Rosuvastatin 10mg
Study: NCT00853970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac Ophthalmic Solution
Description: sterile ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: sterile ophthalmic solution
Study: NCT03658876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose Solution for Injection
Description: 200mg iron sucrose given on 5 successive haemodialysis sessions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Beta
Description: Uptitration of epoetin beta dose. Scale as follows (in units /session): 0-1000-2000-3000-4000-6000-8000-12000
Study: NCT03007004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (2500 units / vial)
Description: BTX-B (E2014, Eisai, NerBloc®) was injected subcutaneously from the palmar side into seven locations around interphalangeal metacarpophalangeal joints, targeting the neurovascular bundles just proximal to the A1 pulley (the radial and ulnar sides of the first finger, the radial side of second finger, the ulnar side of the fifth finger and between the second to fifth fingers). Three locations between the second and third fingers, the third and fourth fingers, and the fourth and fifth fingers were injected with 400 U (0.2 ml) of BTX-B. In addition, the radial and ulnar sides of the first finger, the radial side of the second finger, and the ulnar side of the fifth finger were injected with half a dose of BTX-B (200 units; 0.1 ml). A total of 2000 U (1.0 ml) of BTX-B was injected into one hand. Injections were performed using a 30-gauge needle.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Physiological saline
Description: Saline solution was injected subcutaneously from the palmar side into seven locations around interphalangeal metacarpophalangeal joints, targeting the neurovascular bundles just proximal to the A1 pulley (the radial and ulnar sides of the first finger, the radial side of second finger, the ulnar side of the fifth finger and between the second to fifth fingers). Three locations between the second and third fingers, the third and fourth fingers, and the fourth and fifth fingers were injected with saline (0.2 ml). In addition, the radial and ulnar sides of the first finger, the radial side of the second finger, and the ulnar side of the fifth finger were injected with half a dose of saline (0.1 ml). A total of 1.0 ml of saline was injected into one hand. Injections were performed using a 30-gauge needle.
Study: NCT02551991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nal-IRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study: NCT03751657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Insulin 287 once weekly subcutaneous (s.c.) injections at the starting dose of 70 units. Dose adjustment was done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (insulin 287)
Description: Participants will receive once weekly s.c. injections of placebo equivalent to insulin 287.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is considered as non investigational medicinal product. Subject will continue metformin at stable pre-trial dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is considered as non investigational medicinal product. Subject will continue metformin at stable pre-trial dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase-4 inhibitors
Description: Dipeptidyl peptidase-4 inhibitors are considered as non investigational medicinal products. Subject will continue dipeptidyl peptidase-4 inhibitor at stable pre-trial dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptidyl peptidase-4 inhibitors
Description: Dipeptidyl peptidase-4 inhibitors are considered as non investigational medicinal products. Subject will continue dipeptidyl peptidase-4 inhibitor at stable pre-trial dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Insulin glargine (100 U/mL) once daily s.c. injections at the starting dose of 10 units. Dose adjustment will be done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (insulin glargine)
Description: Participants will receive once daily s.c. injections of placebo equivalent to insulin glargine.
Study: NCT01588418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was administered in random order 30 min before OGTT-PET study in the same subject

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was administered in random order 30 min before OGTT-PET study in the same subject
Study: NCT02601573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose ranging from 800 mg to 1400 mg (total daily dose was based on participant body weight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose ranging from 800 mg to 1400 mg (total daily dose was based on participant body weight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: SOF 400 mg tablet taken q.d. by mouth in the morning with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: SOF 400 mg tablet taken q.d. by mouth in the morning with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: SOF 400 mg tablet taken q.d. by mouth in the morning with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: SOF 400 mg tablet taken q.d. by mouth in the morning with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: SOF 400 mg tablet taken q.d. by mouth in the morning with food.
Study: NCT03393026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 40-160 mg/day for 6 weeks
Study: NCT01052857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture application
Study: NCT02921425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient health record
Description: The study intervention involved the provision to study participants of targeted instruction and practice on use of two features of the Track Health (TH) function of the VA's patient health record (PHR) known as My HealthyVet (MHV) -- Journals and Vitals + Readings -- as a basis for promoting positive physical activity (PA) and dietary lifestyles. Seven interactive multimedia instructional modules were developed by the study team. These modules demonstrated on a computer screen how to enter PA and diet information into the Journals feature; how to add weight data into the Vitals + Readings feature; how to view these and other measures in tabular and graphical formats over different time frames; and the concept of possible cause-effect links between behavioral lifestyle and physiological outcome data. Participants were directed to enter food intake, PA, and weight information a specified number of times per week over the 3-month study period.
Study: NCT01694043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Foods
Description: While watching the tv show, participants will receive a healthy snack to eat (grapes and baby carrots).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Foods
Description: While watching the tv show, participants will receive a healthy snack to eat (grapes and baby carrots).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Foods
Description: While watching the tv show, participants will receive a healthy snack to eat (grapes and baby carrots).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unhealthy Snack Foods
Description: While watching the tv show, participants will receive an unhealthy snack to eat (potato chips and chocolate chip cookies).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unhealthy Snack Foods
Description: While watching the tv show, participants will receive an unhealthy snack to eat (potato chips and chocolate chip cookies).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unhealthy Snack Foods
Description: While watching the tv show, participants will receive an unhealthy snack to eat (potato chips and chocolate chip cookies).
Study: NCT00643383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination drug (Acetaminophen + Tramadol)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02781792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: -Given standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: -Given standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy - Brain
Description: * 23-item questionnaire that can be completed in 5 to 10 minutes with little or no assistance in patients who are not neurologically incapacitated. This brain subscale is usually used along with the core (general) questionnaire \[2\] that includes 27 items.~* Patients rate all 5 items using a five-point Likert scale ranging from 0 not at all to 4 very much. Overall, higher ratings suggest higher QOL. Items are totaled to produce the following subscales, along with an overall QOL score: physical well-being (7 items); social/family well-being (7 items); emotional well-being (6 items); functional well-being (7 items); and concerns relevant to patients with brain tumors (23 items)~* The sleep portion of this questionnaire consists of 17 questions about sleeping patterns and the ability to rate severity of insomnia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy - Brain
Description: * 23-item questionnaire that can be completed in 5 to 10 minutes with little or no assistance in patients who are not neurologically incapacitated. This brain subscale is usually used along with the core (general) questionnaire \[2\] that includes 27 items.~* Patients rate all 5 items using a five-point Likert scale ranging from 0 not at all to 4 very much. Overall, higher ratings suggest higher QOL. Items are totaled to produce the following subscales, along with an overall QOL score: physical well-being (7 items); social/family well-being (7 items); emotional well-being (6 items); functional well-being (7 items); and concerns relevant to patients with brain tumors (23 items)~* The sleep portion of this questionnaire consists of 17 questions about sleeping patterns and the ability to rate severity of insomnia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ActTrust Condor Instrument Watch
Description: -Will be required to wear 24 hours per day and will only be removed at specified data collection time points

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ActTrust Condor Instrument Watch
Description: -Will be required to wear 24 hours per day and will only be removed at specified data collection time points
Study: NCT02229734

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation: Radiotherapy 7 gray (Gy) per week over 5 weeks (35Gy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Suppression
Description: Leuprolide 45mg every 6 months for a total of 18 months
Study: NCT02797119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid 1 g (TA1)
Description: 1 g standard dose tranexamic acid, intravenous unique bolus over 1 minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid 0.5 g (TA1/2)
Description: 0.5 g standard dose tranexamic acid, intravenous unique bolus over 1 minute

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution (TA0)
Study: NCT04529655

Intervention type: DEVICE
Intervention: Capillary Refill Assessment
Description: Device to quantify capillary refill time
Study: NCT00961987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative model
Description: Patients will be referred (if necessary) to an obstetrician who will be co-located in the Maternity Centre and who will be part of the collaborative model of maternity care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: At present, if Maternity Centre patients require the specialized services of an obstetrician, the current standard of care is to refer them to obstetricians located offsite with no professional ties to the Maternity Centre
Study: NCT03181113

Intervention type: DRUG
Intervention: Peginterferon Alfa-2B
Description: pre-received standard peginterferon alfa-2b therapy
Study: NCT04142970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSK3486
Description: HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
Study: NCT03132727

Intervention type: OTHER
Intervention: Pharyngo laryngeal MRI
Description: Patients will be outgoing a pharyngolaryngeal MRI, with injection of gadolinium, in addition to the CT imaging. They will have this MRI in case of doubt about cartilage invasion. It will be realised during the time between the CT imaging and the day of surgery.~Device : gadolinium-based MRI contrast agent This will be realized according to the standard procedure.
Study: NCT04067180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: allogeneic stem cell transplantation with a haplo-identical family donor graft
Description: The graft should preferably be bone marrow, but peripheral stem cells are also acceptable.~Pre-conditioning: thiotepa 5 mg/kg/day for two days (day -6, -5), busulfan at 3,2 mg/kg/day (i.v.) and fludarabine at 50 mg/m2 (i.v.) for three consecutive days (day -4, -3, -2). Intravenous busulfan can be replaced by orally administered busulfan at a dose of 4 mg/kg/day on 3 consecutive days (day -4, -3, -2).~GVHD prophylaxis: cyclophosphamide 50 mg/kg day +3 and +5, cyclosporin A and mycophenolate mofetil.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic stem cell transplantation with a matched unrelated donor graft
Description: Patients are treated according to the standard conditioning protocols developed for URD SCT at each participating center, with a recommendation to use Flu+Bu (fludarabine + busulfan, with a total Bu dose of 8-16 mg/kg body weight orally, or 6,4-12,8 mg/kg i.v.) or Bu+Cy (busulfan + cyclophosphamide, with a dose of Cy not exceeding 50 mg/kg x 2).~The standard GVHD prophylaxis at the center should be applied.
Study: NCT01139437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard Dose HPIV2 Vaccine
Description: 10\^6 tissue culture infectious dose 50% (TCID50) administered intranasally in a single dose